(Q35091746)

6 August 2017

1 reference

title

Treatment of inflammatory bowel disease in childhood: best available evidence (English)

1 reference

inflammatory bowel diseases

6 August 2017

main subject

0 references

inflammation

0 references

author name string

Johanna C Escher

1

1 reference

6 August 2017

Jan A J M Taminiau

2

1 reference

6 August 2017

Edward E S Nieuwenhuis

3

1 reference

6 August 2017

Hans A Büller

4

1 reference

6 August 2017

Richard J Grand

5

1 reference

6 August 2017

publication date

1 January 2003

1 reference

Inflammatory Bowel Diseases

6 August 2017

published in

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

34-58

1 reference

Cortisone in ulcerative colitis; final report on a therapeutic trial.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

A Comparison of Oral Prednisolone Given as Single or Multiple Daily Doses for Active Proctocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

A simple clinical colitis activity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Effects of parenteral nutrition on whole body and extremity composition in children and adolescents with active inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Nutritional therapy of Crohn's disease in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Pediatric Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Meta-analysis of enteral nutrition as a primary treatment of active crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Advances in nutrition and gastroenterology: summary of the 1997 A.S.P.E.N. Research Workshop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Enteral nutrition in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Remission induced by an elemental diet in small bowel Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Supplementary enteral nutrition maintains remission in paediatric Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Mesalamine and relapse prevention in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Frequency of glucocorticoid resistance and dependency in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Long-term effects of budesonide or nedocromil in children with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Effect of long-term treatment with inhaled budesonide on adult height in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Severe hypokalemia after budesonide treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Comparative tolerability of the newer fluoroquinolone antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Saccharomyces boulardii in maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

The role of azathioprine in the management of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

The risk of neoplasms in patients treated with cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Use of infliximab in the treatment of Crohn's disease in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Use of infliximab in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Infliximab as a novel therapy for pediatric ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

The relationship between infliximab treatment and lymphoma in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Thalidomide-induced sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Low-Dose Cyclosporine for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200301000-00006

10.1097/00054725-200301000-00006

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference